According to Boehringer Ingelheim, the United Kingdom, Croatia, Slovakia, Denmark, Norway, Ireland, Austria, Romania and Spain have approved the Spiolto Respimat tiotropium/olodaterol SMI for the treatment of COPD. BI recently announced the launch of the tiotropium/olodaterol soft mist inhaler in the US, where it is marketed as Stiolto Respimat.
Boehringer Ingelheim Chief Medical Officer Klaus Dugi said, “Since its first launch in 2002, Spiriva has brought medical benefits that have made a real difference to the lives of millions of patients with COPD around the world. Spiolto Respimat is our newest advance in COPD treatment. Its recent approval in the US, Canada and Australia, alongside the approval in countries across Europe, is an important step forward in our ongoing commitment to provide effective solutions for patients with COPD. We anticipate further approvals of Spiolto Respimat in other European countries over the coming months.”
Read the Boehringer Ingelheim press release.
